760 F.Supp.3d 184
D.N.J.2024Background
- Janssen sued Teva for infringement of U.S. Patent No. 9,439,906, which claims specific dosing regimens for paliperidone palmitate (Invega Sustenna); Teva stipulated infringement but challenged invalidity.
- The asserted regimen (representative Claim 2) prescribes deltoid loading doses of ~150 mg‑eq then ~100 mg‑eq (day 1 and day 6–10) followed by monthly maintenance (25–150 mg‑eq); other claims cover renal‑impairment dosing and a nanoparticle formulation (d50 ~900–1600 nm).
- The closest prior art was the ’548 Protocol (Phase III plan) proposing equal gluteal doses (50/100/150 mg‑eq) with no reported results; Teva also relied on Janssen patents (’544), WO ’384, and older LAI literature.
- On initial bench trial the court found the patent not invalid for obviousness or indefiniteness; the Federal Circuit affirmed indefiniteness but remanded the obviousness holding; on remand this court again holds the patent not proven invalid.
- The court’s analysis focused on: (1) whether a POSA would have been motivated to modify/combine the prior art to arrive at the claimed specific regimen, and (2) whether a POSA would have had a reasonable expectation of success—finding Teva failed on both.
- The court also credited objective indicia (long‑felt need, commercial success, unexpected results, industry skepticism) and found prior art teachings (notably the ’544 Patent) taught away from some claimed features.
Issues
| Issue | Janssen's Argument | Teva's Argument | Held |
|---|---|---|---|
| Obviousness of Claim 2 (150/100 mg‑eq. loading regimen; deltoid administration) | The claimed regimen is novel and nonobvious; prior art would not have motivated or given reasonable expectation of success to arrive at the specific unequal/decreasing loading sequence and deltoid/site/maintenance relationship. | POSA would have modified the ’548 Protocol using known teachings (including other references) to reach the claimed regimen; dosage totals overlap prior ranges. | Court: Teva failed by clear and convincing evidence to show motivation and reasonable expectation of success; Claim 2 nonobvious. |
| Motivation to combine and reasonable expectation of success from prior art | Motivation must be tied to credible prior art and POSA expectations; Janssen argued prior art lacked results and taught different approaches (e.g., change particle size rather than dose). | Teva relied on ’548 Protocol plus other references (Ereshefsky, Haldol label, ’544, WO ’384) to motivate changes and predict success. | Court: POSA would not have been credibly motivated to make the specific modifications nor expected success; Teva’s expert testimony and cited references were unpersuasive or contradicted. |
| Obviousness of renal‑impairment claims (Claims 10 & 13) | Claims address dosing for renally impaired patients and are not obvious because prior art does not support the specific reductions or teach the claimed ranges. | A POSA would apply straightforward percentage reductions (e.g., 50%) to ’548 Protocol dosing to reach renally‑adjusted claims. | Court: Teva failed to show motivation to make the claimed reductions (record and Cleton 2007/labels do not support Teva’s theory); claims 10 and 13 nonobvious. |
| Obviousness of particle‑size/formulation claims (Claims 20 & 21) | Dependent on nonobvious independent claims; the ’544 Patent taught away from the particular particle size/formulation embodied by the claims. | Teva argued particle size overlaps prior disclosures and is result‑effective/optimizable. | Court: ’544 Patent taught away from the disputed formulation (Formulation B); dependent claims nonobvious. |
Key Cases Cited
- KSR Int’l Co. v. Teleflex Inc., 550 U.S. 398 (2007) (obviousness standard: flexible, consider inferences and ordinary creativity in combining prior art)
- Graham v. John Deere Co., 383 U.S. 1 (1966) (framework for obviousness: scope/content of prior art, differences, level of skill, secondary considerations)
- Janssen Pharms., Inc. v. Teva Pharms. USA, Inc., 97 F.4th 915 (Fed. Cir. 2024) (Federal Circuit opinion remanding obviousness analysis and directing focus on POSA expectations from NCT 548)
- Janssen Pharms., Inc. v. Tolmar, Inc., 718 F. Supp. 3d 394 (D. Del. 2024) (parallel district‑court decision finding ’906 patent nonobvious; used as persuasive record comparison)
- In re Applied Materials, Inc., 692 F.3d 1289 (Fed. Cir. 2012) (overlap of claimed ranges and prior art ranges can create prima facie obviousness)
- E.I. DuPont de Nemours & Co. v. Synvina C.V., 904 F.3d 996 (Fed. Cir. 2018) (presumption of obviousness from range overlap; rebuttable)
- In re Kumar, 418 F.3d 1361 (Fed. Cir. 2005) (range‑overlap presumption applies only when range/value difference is the sole distinction)
- OSI Pharms., LLC v. Apotex Inc., 939 F.3d 1375 (Fed. Cir. 2019) (absence of efficacy data in prior art affects reasonable‑expectation‑of‑success analysis)
- Intelligent Bio‑Sys., Inc. v. Illumina Cambridge Ltd., 821 F.3d 1359 (Fed. Cir. 2016) (patent challenger must show both motivation to combine and reasonable expectation of success)
- Allergan, Inc. v. Sandoz Inc., 796 F.3d 1293 (Fed. Cir. 2015) (unexpected results can rebut a prima facie case of obviousness)